Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 7/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | GLA | P06280 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 4/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 2/20 | 0.39 |
| ▸ | PIM1 | P11309 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.38 |
| ▸ | DAPK3 | O43293 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19859238 | 0.87 | ALDH1A1 (0.42) | MAPTKMT2AALDH1A1GLAPOLB | |
| SCHEMBL21074348 | 0.87 | PRKCB (0.44) | MAPTKMT2AALDH1A1GLAPOLB | |
| SCHEMBL29801729 | 0.87 | PRKCB (0.44) | MAPTKMT2AALDH1A1GLAPOLB | |
| SCHEMBL29801609 | 0.87 | ALDH1A1 (0.42) | MAPTKMT2AALDH1A1GLAPOLB | |
| SCHEMBL29801526 | 0.86 | PTGS1 (0.42) | MAPTKMT2AALDH1A1GLAPOLB | |
| SCHEMBL19859148 | 0.86 | PTGS1 (0.42) | MAPTKMT2AALDH1A1GLAPOLB | |
| SCHEMBL23361928 | 0.84 | MEN1 (0.39) | MAPTKMT2AALDH1A1POLBHTT | |
| SCHEMBL21048269 | 0.84 | MEN1 (0.39) | MAPTKMT2AALDH1A1POLBHTT | |
| SCHEMBL19859142 | 0.84 | MAPT (0.40) | MAPTKMT2AALDH1A1POLBMEN1 | |
| SCHEMBL29801653 | 0.84 | MAPT (0.40) | MAPTKMT2AALDH1A1POLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114929217-A | Pharmaceutical composition for treating multiple sclerosis based on AMPK inhibitory function and zinc homeostasis control function | 锌医疗公司 | 2022-08-19 | — | — | CN | claimed |
| US-12343335-B2 | Pharmaceutical composition for treating multiple sclerosis on basis of AMPK inhibitory function and zinc homeostasis control function | ZINCURE CORP. (KR) | 2025-07-01 | — | — | US | disclosed |
| US-20230000839-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION | ZINCURE CORP. (KR) | 2023-01-05 | — | — | US | disclosed |
| US-20230000839-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION | ZINCURE CORP. (KR) | 2023-01-05 | — | — | US | disclosed |
| CN-114929217-A | Pharmaceutical composition for treating multiple sclerosis based on AMPK inhibitory function and zinc homeostasis control function | 锌医疗公司 | 2022-08-19 | — | — | CN | disclosed |
| EP-3498277-B1 | PHARMACEUTICAL COMPOSITION FOR STROKE TREATMENT BASED ON AMPK INHIBITION | ZINCURE CORP (KR) | 2021-10-06 | — | — | EP | disclosed |
| US-20190167647-A1 | PHARMACEUTICAL COMPOSITION FOR STROKE TREATMENT BASED ON AMPK INHIBITION | ZINCURE CORP. (KR) | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230000839-A1 | PHARMACEUTICAL COMPOSITION FOR TREATING MULTIPLE SCLEROSIS ON BASIS OF AMPK INHIBITORY FUNCTION AND ZINC HOMEOSTASIS CONTROL FUNCTION | PRKAB1, PRKAB2, PRKAG1 | MAPT 517/4885KMT2A 2170/4885ALDH1A1 3057/4885 |
| US-20190167647-A1 | PHARMACEUTICAL COMPOSITION FOR STROKE TREATMENT BASED ON AMPK INHIBITION | PRKAG1, PRKAB1, PRKAG2 | MAPT 446/4885KMT2A 2053/4885ALDH1A1 417/4885 |
| US-12343335-B2 | Pharmaceutical composition for treating multiple sclerosis on basis of AMPK inhibitory function and zinc homeostasis control function | PRKAB1, PRKAB2, PRKAG1 | MAPT 517/4885KMT2A 2170/4885ALDH1A1 3057/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.